Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adaptive Evolution of Serotype O Foot-and-Mouth Disease Virus Under Vaccine Pressure: Combined VP1 T142/Q153 Mutations Drive Antigenic Alteration and Immune Evasion.

Transboundary and emerging diseases·2026

Same author

Muscles as Basic Therapeutic Units in Glabellar Botulinum Toxin Injection: Technique Description and Preliminary Clinical Experience.

Aesthetic plastic surgery·2026

Same author

Sunlight-Driven Concurrent Synthesis of Jet Fuel Precursors and Hydrogen From Biomass-Derived Furfuryl Alcohol Over Oxygen-Doped Zn<sub>2</sub>In<sub>2</sub>S<sub>5</sub>.

Advanced materials (Deerfield Beach, Fla.)·2026

Same author

A divalent nanoparticle vaccine confers robust protective immunity against serotype O FMDV and SVA in pigs.

Veterinary microbiology·2026

Same author

Human papillomavirus in prostate cancer: examining the evidence for a co-factor role.

Frontiers in microbiology·2026

Same author

Decoupling and De Novo Design of Flexible Polymeric Films for High-Temperature Triboelectric Sensing and Electromagnetic Shielding.

Advanced materials (Deerfield Beach, Fla.)·2026

Search research articles

Related Experiment Video

Updated: Feb 27, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

A Novel Inactivated Vaccine Based on an Emerging PEDV GIIc Variant Provides Cross-Protection Against Heterologous GII

Jingjing Xu¹, Ningning Fu¹, Zimin Liu¹

¹Shanghai ShenLian Biomedical Corporation, Shanghai 200241, China.

|February 26, 2026

Summary

A new inactivated vaccine using an emerging porcine epidemic diarrhea virus (PEDV) GIIc variant shows promise. This PEDV vaccine elicits strong immunity and offers cross-protection against other GII strains, aiding control efforts.

Keywords:

GIIc strain cross-protection against heterologous GII strains inactivated vaccine pathogenicity porcine epidemic diarrhea virus

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

Related Experiment Videos

Last Updated: Feb 27, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

Area of Science:

Veterinary Virology
Immunology
Swine Health

Background:

Porcine epidemic diarrhea virus (PEDV) GII genotype poses a significant threat to the swine industry.
Existing vaccines offer limited cross-protection against emerging, heterogeneous PEDV variants.
Maternal immunity is a primary goal of current PEDV vaccination strategies.

Purpose of the Study:

To develop a novel inactivated vaccine against an emerging PEDV GIIc variant.
To evaluate the immunogenicity of this new vaccine.
To assess its cross-protective efficacy against heterologous PEDV strains.

Main Methods:

Isolation and identification of a novel pathogenic PEDV strain (PEDV-HeN2024).
Preparation of an inactivated vaccine using ISA 201 VG adjuvant.
Assessment of immunogenicity (antibody titers, IgG levels) and cross-protection (in vitro neutralization, in vivo challenge studies).

Main Results:

The isolated PEDV-HeN2024 strain caused severe disease and mortality in piglets.
Vaccinated piglets developed potent cross-neutralizing antibodies against homologous and heterologous strains.
Vaccination significantly protected piglets from clinical signs, viral shedding, and intestinal damage.

Conclusions:

The novel inactivated PEDV GIIc vaccine induces robust humoral immunity.
This vaccine provides cross-protection against prevalent heterologous GII strains.
It shows potential as a broad-spectrum vaccine for controlling PEDV outbreaks.